Skip to main content
ACOG
NASDAQ Life Sciences

Alpha Cognition Reports Widened Q1 Loss & High Cash Burn, Discloses Material Weakness

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$5.68
Mkt Cap
$123.677M
52W Low
$4.5
52W High
$11.54
Market data snapshot near publication time

summarizeSummary

Alpha Cognition reported a substantial increase in Q1 net loss and cash burn, alongside a material weakness in internal controls, despite strong product revenue growth.


check_boxKey Events

  • Net Loss Widens Significantly

    The company reported a net loss of $6.48 million for Q1 2026, a 275% increase compared to $1.73 million in Q1 2025.

  • Cash Burn Accelerates

    Cash used in operating activities increased by 477% to $11.8 million in Q1 2026, compared to $2.04 million in Q1 2025. Cash and cash equivalents stood at $54.2 million at quarter-end.

  • Material Weakness in Internal Controls Disclosed

    Management identified a material weakness in internal control over financial reporting due to inadequate accounting procedures for complex transactions and insufficient segregation of duties.

  • Strong Product Revenue Growth

    Product revenue from ZUNVEYL increased by 910% to $3.5 million in Q1 2026, demonstrating significant commercial progress.


auto_awesomeAnalysis

Alpha Cognition Inc. reported a significantly widened net loss and a substantial increase in cash burn for Q1 2026, raising immediate liquidity concerns. The company used $11.8 million in operating activities, a 477% increase from the prior year, leaving $54.2 million in cash and equivalents at quarter-end. This cash balance is further reduced by a $6.15 million royalty settlement paid in April 2026. The net loss surged by 275% to $6.48 million, driven by a 101% increase in selling, general, and administrative expenses and a 174% rise in R&D. Additionally, management disclosed a material weakness in internal control over financial reporting, citing inadequate accounting procedures for warrants, stock options, and deferred tax disclosures, along with a lack of segregation of duties. While product revenue from ZUNVEYL grew by an impressive 910%, the rapid increase in expenses and the governance issue present significant challenges.

At the time of this filing, ACOG was trading at $5.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.7M. The 52-week trading range was $4.50 to $11.54. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ACOG - Latest Insights

ACOG
May 14, 2026, 4:15 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
ACOG
May 14, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
ACOG
May 01, 2026, 4:40 PM EDT
Filing Type: 8-K/A
Importance Score:
7
ACOG
Apr 20, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
ACOG
Apr 14, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
8
ACOG
Apr 01, 2026, 5:18 PM EDT
Source: Reuters
Importance Score:
8
ACOG
Mar 31, 2026, 5:09 PM EDT
Filing Type: 10-K
Importance Score:
7
ACOG
Mar 26, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
7
ACOG
Mar 26, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
ACOG
Mar 04, 2026, 4:05 PM EST
Filing Type: 4
Importance Score:
7